Nov 29, 2022 / 06:00PM GMT
David D. Chang - Allogene Therapeutics, Inc. - Co-Founder, President, CEO & Director
It's so great to see so many of you in the room in person. It has been long overdue. Welcome, and thank you for joining us today in our R&D Showcase. As I said, many of you are here in this room, but there are a lot more who are joining us online. My name is David Chang, President and CEO and Co-Founder of Allogene.
Many of us have been immersed in cell therapy and sometimes forget to realize that we are in the early days of creating a new modality that many -- that is unlike any before it. A single infusion that can induce deep and durable responses where we now talk about the possibility of cure, even in the advanced and refractory disease setting.
CD19 CAR T trial had a humble beginning as an investigator-sponsored academic trial in 2019, but quickly gained the momentum as early reports of complete remission were published a few years later. That got the attention of many in biotech, leading to approval of the first autologous CAR T directed therapies at CD19 in 2017, YESCARTA and KYMRIAH.
Allogene Therapeutics Inc R&D Showcase Transcript
Nov 30, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers